Group 1: Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is involved in the production of heparin and related products [2] - The company has received registration approval for its new product, Dahuansuan, and has passed the new GMP certification [2] Group 2: Product Development and Market Strategy - The company is actively developing new products, including low molecular weight heparin and Eptifibatide, which are currently awaiting approval [2] - The market for hyaluronic acid appears promising, although current production levels are low [3] Group 3: Supply Chain and Production - The company primarily sources heparin raw materials domestically, with foreign procurement being a minor part [3] - The production workshop for formulations is built according to FDA standards [3] Group 4: Market Coverage and Sales - The low molecular weight heparin injection has approximately 50% coverage in top-tier hospitals, with nearly 2,000 hospitals nationwide using the product [3] - The company’s Dahuansuan raw material is mainly for internal use, while the Jiangsu subsidiary sells its heparin sodium raw materials externally [3]

证券代码：300255 证券简称：常山药业 编号：2014-5 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------|----------------|--------------------|----------------------------------------|----------------------------------------------------| | | √ 特定对象调研 | □ | 分析师会议 | | | 投资者关系活动 | □ 媒体采访 | □ | 业绩说明会 | | | 类别 | □ 新闻发布会 | □ | 路演活动 | | | | □ 现场参观 | | | | | | □ 其他 | | （请文字说明其他活动内容） | | | | 国泰君安 | 王超伟 | 长安基金 | 杨小馨 | | 参与单位名称及 | 千石创富 | 陈仕飞 | 民生证券 | 张金洋 | | 人员姓名 | 兴业证券 | 徐佳熹 | 中航证券 | 胡厚中等 | | 时间 | 2014 年 11 | 月 6 ...

证券代码：300255 证券简称：常山药业 河北常山生化药业股份有限公司 投资者关系活动记录表 编号：2015-1 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 宏道投资 杨洁 | 全尔晖 | | 人员姓名 | 天安财险 党新星 | | | | | | | 时间 | 2015 年 10 月 29 日 | 上午 9:45 | | 地点 | | 河北常山生化药业股份有限公司会议室 | | 上市公司接待人 | 董事会秘书 : 张威 | | | 员姓名 | | | | | | 一、董秘张威介绍了公司三季度经营情况 | | | 二、就公 ...

Group 1: Company Overview and Market Position - The price of heparin sodium raw materials is currently at a relatively low point, with limited downward space [2] - The new low molecular weight heparin raw material workshop has passed German GMP and US FDA certification, which is expected to become a growth point for the company [2] - Sales of low molecular weight heparin calcium injection have been steadily increasing in recent years, and the company's first generic drug, heparin sodium injection, has entered the market and is expected to achieve rapid growth [2] Group 2: Future Plans and Collaborations - The company plans to export heparin preparations to Europe and the US, having already partnered with D.Med Healthcare GmbH&Co.KG in Germany to establish a joint venture for secondary packaging to sell in the European market [2] - The first blood dialysis center is being standardized and has been completed, awaiting expert group acceptance [3] - Clinical trials for Abiraterone have entered Phase I [3] Group 3: Product Development and Regulatory Status - The supplementary application for sildenafil raw materials and formulations was submitted to the National Medical Products Administration in the first half of 2015 and has been accepted; the corresponding production workshop is completed and awaits drug registration approval and GMP certification [3] - The bidding results for low molecular weight heparin calcium injection this year have been good, with stable winning prices; the heparin sodium injection is in the gradual development stage due to its new market entry [3] - The company is currently producing cosmetic-grade and food-grade hyaluronic acid in its pilot workshop, with a new production workshop under construction [3]

Group 1: Company Overview and Sales Performance - The company is actively expanding its low molecular weight heparin calcium injection sales, showing stable growth compared to the same period last year [2] - The sales of Daptomycin injection are expected to see significant growth as the company actively develops the market [2] - The heparin raw material sales are anticipated to experience good growth this year due to negotiations with several large clients [2] Group 2: Product Development and Market Strategy - The company is preparing registration materials for sodium hyaluronate, with strong market demand, particularly in the beauty industry [3] - Plans are in place to develop injectable-grade sodium hyaluronate in the future [3] - The company is preparing registration materials for heparin and low molecular weight heparin formulations for international market entry [3] Group 3: Clinical Trials and New Initiatives - The first phase of clinical trials for Abexinostat is expected to be completed in Q3 of this year, with preparations for the second phase already underway [3] - The company is set to open its first blood dialysis center and is committed to ensuring operational quality [3] - Future collaborations include establishing a specialized oncology hospital in China with a U.S. partner and developing new anti-tumor drugs [3]

Group 1: Company Overview and Operations - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is focused on the development of hyaluronic acid and heparin series products [1] - The company is currently preparing to apply for production of injectable hyaluronic acid to the National Medical Products Administration [1] - The new hyaluronic acid workshop is designed with a production capacity of 20 tons, while the current capacity for food-grade and cosmetic-grade hyaluronic acid is approximately 1,000 kg [2] Group 2: Product Development and Clinical Trials - The company is collaborating with American Huangxinxiang to develop a new diabetes treatment, Aibennate, which is currently in Phase I clinical trials and progressing well [2] - The company plans to produce pharmaceutical-grade, food-grade, and cosmetic-grade products in the new hyaluronic acid workshop [2] Group 3: Market Strategy and Future Plans - The company is exploring acquisition opportunities in the pharmaceutical, medical services, and medical device sectors to support strategic growth [3] - The company aims to establish a blood dialysis center to meet the demand in Shijiazhuang and surrounding areas, addressing the current shortfall in public hospital capacity [3] - The independent dialysis center will focus on providing superior service and hygiene compared to public hospitals, leveraging collaboration with German D-Med for advanced dialysis standards [3]

证券代码：300255 证券简称：常山药业 编号：2016-3 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明 ...

Financial Performance - The company's revenue for Q3 2022 was ¥647,277,328.34, a decrease of 12.65% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥2,528,324.29, down 94.96% year-on-year[7]. - The basic earnings per share (EPS) was ¥0.0027, reflecting a decline of 94.96% compared to the previous year[7]. - Total operating revenue for the current period is ¥1,793,779,750.02, a decrease of 17% compared to ¥2,158,441,271.38 in the previous period[28]. - The net profit for the current period is 61,239,360.42, a decrease from 205,052,547.28 in the previous period, representing a decline of approximately 70.1%[30]. - The total comprehensive income for the current period is 56,628,177.82, compared to 196,009,872.74 in the previous period, indicating a decrease of about 71.1%[33]. - The basic and diluted earnings per share for the current period are both 0.0720, down from 0.2215 in the previous period, reflecting a decline of approximately 67.5%[33]. - The operating profit for the current period is 86,207,188.49, a significant decrease from 232,565,881.24 in the previous period, reflecting a decline of about 62.9%[30]. - The total profit for the current period is 83,704,368.74, down from 231,578,978.91 in the previous period, indicating a decrease of approximately 63.8%[30]. Assets and Liabilities - Total assets increased by 11.07% to ¥5,764,437,750.03 compared to the end of the previous year[7]. - The company's total assets reached ¥5,764,437,750.03, up from ¥5,189,848,787.26, showing growth in asset base[27]. - Non-current liabilities increased to ¥701,618,091.58 from ¥383,684,965.68, indicating potential leverage for future investments[27]. - The total liabilities of the company are now ¥2,659,585,565.72, compared to ¥2,117,729,197.94 in the previous period, reflecting increased borrowing[27]. - The company's equity attributable to shareholders increased to ¥3,107,567,055.77 from ¥3,068,784,360.68, showing a slight growth in shareholder value[27]. Cash Flow - The company reported a net cash flow from operating activities of -¥183,723,082.26, a decrease of 29.24% year-to-date[7]. - Cash flow from operating activities shows a net outflow of -183,723,082.26, compared to -142,157,545.23 in the previous period, indicating a worsening cash flow situation[34]. - Cash inflow from financing activities is 1,859,945,742.67, an increase from 1,336,493,978.00 in the previous period, representing a growth of about 39.2%[36]. - The cash and cash equivalents at the end of the period amount to 384,734,470.51, down from 517,516,379.54 in the previous period, a decrease of approximately 25.7%[36]. Shareholder Information - The number of shares held by the largest shareholder, Gao Shuhua, is 333,644,728, representing 35.69% of total shares[14]. - The total number of shares held by the top ten shareholders includes 333,644,728 shares held by Gao Shuhua, representing the largest single holding[17]. - The company repurchased a total of 15,906,000 shares, accounting for 1.70% of the total share capital[17]. - The company plans to unlock 25% of the shares held by executives annually during their tenure, with specific unlock dates set for certain shareholders[18]. - The total number of restricted shares at the end of the period was 2,656,757, with a significant portion being released due to executive departures[20]. - The company reported a total of 11,500,000 shares held in a credit trading guarantee account by shareholder Chen Xi, indicating active participation in financing activities[17]. - The company has not disclosed any related party relationships among the top ten shareholders, nor whether they are acting in concert[17]. Expenses - Sales expenses decreased by 38.72% year-on-year, primarily due to reduced marketing expenses[13]. - Financial expenses increased by 43.25% year-on-year, mainly due to higher interest from increased bank loans[13]. - Research and development expenses increased to ¥115,423,336.21 from ¥106,404,718.54, indicating a continued focus on innovation[28]. Market Outlook - The company plans to expand its market presence and enhance product offerings in the upcoming quarters[29]. - The company reported a net profit margin improvement, indicating better cost management and operational efficiency[29].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,146,502,421.68, a decrease of 19.11% compared to ¥1,417,401,504.14 in the same period last year[28]. - The net profit attributable to shareholders of the listed company was ¥64,761,136.23, down 58.74% from ¥156,960,062.38 in the previous year[28]. - The net profit after deducting non-recurring gains and losses was ¥62,378,790.31, a decline of 59.14% compared to ¥152,666,257.93 in the same period last year[28]. - The net cash flow from operating activities was -¥282,443,577.36, a significant decrease of 338.16% from ¥118,591,701.88 in the previous year[28]. - Basic earnings per share were ¥0.07, down 58.82% from ¥0.17 in the same period last year[28]. - The company's operating revenue for the reporting period was ¥1,146,502,421.68, a decrease of 19.11% compared to ¥1,417,401,504.14 in the same period last year, primarily due to a decline in sales of low molecular heparin preparations and heparin raw materials[63]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,820,185,840.37, an increase of 12.15% from ¥5,189,848,787.26 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company were ¥3,106,056,745.99, a slight increase of 1.21% from ¥3,068,784,360.68 at the end of the previous year[28]. - The company's total assets included cash and cash equivalents of ¥678,516,099.25, representing 11.66% of total assets, an increase from 10.47% the previous year due to increased bank loans[68]. - The inventory level rose to ¥2,578,695,116.73, accounting for 44.31% of total assets, reflecting an increase in raw material costs[68]. - The company's short-term borrowings increased to ¥1,760,597,759.94, representing 30.25% of total assets, up from 23.74% the previous year, attributed to increased bank loans[68]. Market Position and Product Development - The company maintains a leading position in the domestic low molecular weight heparin market, with its core product, low molecular weight heparin calcium injection, recognized widely and holding a dominant market share[38]. - The company is actively developing a new Class I drug, a long-acting GLP-1 formulation for treating type 2 diabetes, which is currently in phase III clinical trials[39]. - The company is expanding its product line to include new products such as sildenafil citrate, in addition to its heparin and hyaluronic acid products[41]. - The company is focusing on improving the efficiency of fund usage and enhancing the economic benefits of its projects[88]. - The company is committed to balancing generic and innovative drug development to manage risks associated with new product research[121]. Research and Development - The company's R&D investment increased by 15.94% to ¥108,557,893.89 from ¥93,630,517.91 in the previous year, indicating a focus on innovation and product development[63]. - The company plans to increase investment in R&D for heparin series products, hyaluronic acid series products, and new drug development in the coming years[61]. - The company is advancing the clinical trials for Abenatide injection and two new anti-tumor drugs, with all participant enrollments completed as planned[52]. Environmental Compliance - The company processed a total of 21,893.78 tons of wastewater in the first half of 2022, with no instances of exceeding discharge standards[141]. - The wastewater treatment facility at the company operated smoothly throughout the year, ensuring compliance with discharge standards[141]. - The company received environmental impact assessment approvals for multiple projects, including a 35-ton heparin raw material project in October 2021[143]. - The company obtained a national pollutant discharge permit valid until May 6, 2027[144]. - The company has implemented a comprehensive waste gas treatment system that meets regulatory standards throughout its facilities[142]. Risks and Challenges - The company faces risks related to policy and industry changes, intensified market competition, and new business risks[6]. - The company is facing risks from policy changes in the pharmaceutical industry, which could impact operational performance if not adapted to promptly[116]. - The company anticipates increased operating costs due to rising sales and research expenses as it expands its market presence[123]. Subsidiary Performance - The subsidiary Hebei Changshan Jiukang Biotechnology Co., Ltd. reported a net loss of 25,717,141.90 CNY[95]. - The subsidiary Hebei Changshan Kaikede Biotechnology Co., Ltd. reported a net loss of 7,033,615.50 CNY[97]. - The company reported a net profit of 10,394,261.61 yuan from its Hong Kong subsidiary, primarily from the export of raw materials[112]. - The Jiangsu subsidiary achieved a net profit of 998,731.56 yuan, mainly from the sale of low molecular heparin calcium raw materials[111]. Financial Management - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[176]. - There were no violations regarding external guarantees during the reporting period[177]. - The semi-annual financial report was not audited[178]. - The company did not experience any major litigation or arbitration matters during the reporting period[182]. - There were no significant related party transactions during the reporting period[190].

Financial Performance - The company's operating revenue for Q1 2022 was ¥574,179,074.10, a decrease of 19.18% compared to ¥710,471,945.23 in the same period last year[4] - Net profit attributable to shareholders was ¥29,651,405.14, down 56.75% from ¥68,564,864.13 year-on-year[4] - Basic earnings per share decreased to ¥0.03, down 57.14% from ¥0.07 in the same period last year[4] - Net profit for the current period was ¥28,851,938.26, down 57.5% from ¥67,763,683.84 in the previous period[31] - The total comprehensive income for the current period was ¥27,186,973.03, down from ¥67,650,342.85 in the previous period[34] Cash Flow - The net cash flow from operating activities was -¥158,674,887.67, a decline of 312.95% compared to ¥74,511,494.41 in the previous year[4] - The cash inflow from operating activities totaled ¥570,204,153.47, a decrease of 26.3% compared to ¥773,417,974.82 in the previous period[35] - The cash outflow from operating activities amounted to ¥728,879,041.14, an increase of 4.3% from ¥698,906,480.41 in the prior period[38] - The net cash flow from investment activities was -¥143,068,776.56, compared to -¥26,001,230.73 in the previous period[38] - Cash inflow from financing activities was ¥439,130,477.50, with a net cash flow of ¥359,162,655.61 after outflows[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,597,062,348.40, an increase of 7.85% from ¥5,189,848,787.26 at the end of the previous year[4] - Current assets amounted to CNY 3,664,314,908.73, up from CNY 3,408,485,410.19 at the beginning of the year, indicating a growth of approximately 7.5%[21] - Total liabilities increased to ¥2,497,755,786.05 from ¥2,117,729,197.94, representing a growth of 17.9%[27] - Non-current liabilities rose to ¥531,455,411.42 from ¥383,684,965.68, an increase of 38.6%[27] - The company’s total liabilities increased, with short-term borrowings being a significant component of the total liabilities[21] Expenses - Total operating costs decreased to ¥542,640,735.36 from ¥629,075,497.31, reflecting a reduction of 13.7%[28] - The company experienced a 44.69% decrease in selling expenses, attributed to the reduction in sales revenue[9] - Research and development expenses for the current period were ¥36,139,354.53, a decrease of 11.5% from ¥40,999,115.40 in the previous period[28] Other Financial Metrics - The weighted average return on net assets was 0.96%, down 1.42% from 2.38% in the same period last year[4] - The company reported a foreign exchange loss of ¥1,408,421.45, compared to a loss of ¥1,360,520.62 in the previous period[31] - The total equity attributable to shareholders of the parent company was ¥3,096,770,800.59, up from ¥3,068,784,360.68, a growth of 0.9%[27] - The company reported accounts receivable of CNY 282,556,880.93, down from CNY 293,346,231.91, indicating a decrease of approximately 3%[21] Shareholder Information - The company repurchased 15,906,000 shares in 2020, accounting for 1.70% of the total share capital[14] - The total number of restricted shares at the end of the period was 253,514,027, with 168,450 shares released during the period[17]